drugset / Trial / NCT04056429

Multiregion BHA in Open Tibia Fractures

NCT04056429 ↗

RandomizedParallel-groupDouble-blindTreatment

Summary

This clinical study is being conducted to demonstrate the safety and effectiveness of the Bone Healing Accelerant (BHA) product when applied to tibia (leg bone) fractures with an external wound or skin break (also called open tibia fractures). It is hypothesized that by 6 months, the number of subjects with successful bone healing will be greater in the BHA-treated group compared to subjects treated with standard of care alone. Open tibia fractures were chosen for this study because healing rates are typically longer than for other bone fractures due to the limited vascular supply, limited soft tissue coverage, and higher risk of infection.

Timeline

Start
2026-07
Primary completion
2028-09
Completion
2028-09

Outcome

Outcome not reported

Stopped: “study never started and is delayed until further notice”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bone Healing Accelerant Unknown — Other

Indications

No indication recorded.